Development and Validation of an Explainable Machine Learning-Based Prediction Model for Drug-Food Interactions from Chemical Structures.
Quang-Hien KhaViet-Huan LeTruong Nguyen Khanh HungNgan Thi Kim NguyenNguyen-Quoc-Khanh LePublished in: Sensors (Basel, Switzerland) (2023)
Possible drug-food constituent interactions (DFIs) could change the intended efficiency of particular therapeutics in medical practice. The increasing number of multiple-drug prescriptions leads to the rise of drug-drug interactions (DDIs) and DFIs. These adverse interactions lead to other implications, e.g., the decline in medicament's effect, the withdrawals of various medications, and harmful impacts on the patients' health. However, the importance of DFIs remains underestimated, as the number of studies on these topics is constrained. Recently, scientists have applied artificial intelligence-based models to study DFIs. However, there were still some limitations in data mining, input, and detailed annotations. This study proposed a novel prediction model to address the limitations of previous studies. In detail, we extracted 70,477 food compounds from the FooDB database and 13,580 drugs from the DrugBank database. We extracted 3780 features from each drug-food compound pair. The optimal model was eXtreme Gradient Boosting (XGBoost). We also validated the performance of our model on one external test set from a previous study which contained 1922 DFIs. Finally, we applied our model to recommend whether a drug should or should not be taken with some food compounds based on their interactions. The model can provide highly accurate and clinically relevant recommendations, especially for DFIs that may cause severe adverse events and even death. Our proposed model can contribute to developing more robust predictive models to help patients, under the supervision and consultants of physicians, avoid DFI adverse effects in combining drugs and foods for therapy.
Keyphrases
- artificial intelligence
- machine learning
- end stage renal disease
- adverse drug
- chronic kidney disease
- healthcare
- newly diagnosed
- ejection fraction
- drug induced
- big data
- human health
- high resolution
- patient reported outcomes
- emergency department
- deep learning
- peritoneal dialysis
- mental health
- early onset
- mesenchymal stem cells
- risk assessment
- cell therapy
- smoking cessation
- social media